BiotechTube

Saquinavir

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

IDV Associated Nephrotoxicity

Conditions

IDV Associated Nephrotoxicity

Trial Timeline

May 1, 2004 → May 1, 2008

NCT ID
NCT00477048

About Saquinavir

Saquinavir is a phase 2 stage product being developed by Roche for IDV Associated Nephrotoxicity. The current trial status is completed. This product is registered under clinical trial identifier NCT00477048. Target conditions include IDV Associated Nephrotoxicity.

What happened to similar drugs?

16 of 20 similar drugs in IDV Associated Nephrotoxicity were approved

Approved (16) Terminated (4) Active (4)
✅Tamsulosin OCASAstellas PharmaApproved
✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved
✅Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
✅Imipenem + ImipenemMerckApproved
✅cyclosporine micro-emulsionNovartisApproved
✅Avacopan, prednisolone and rituximab + Prednisolone and rituximabKissei PharmaceuticalApproved
✅Avacopan + Placebo + Standard of CareAmgenApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT00002383Phase 1Completed
NCT00002382Phase 3Completed
NCT00002425ApprovedCompleted
NCT00002229ApprovedCompleted
NCT00477048Phase 2Completed

Competing Products

20 competing products in IDV Associated Nephrotoxicity

See all competitors
ProductCompanyStageHype Score
Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2Dr. Reddy's LaboratoriesPhase 2
32
Nanatinostat in combination with valganciclovirViracta TherapeuticsPhase 2
17
SatralizumabChugai PharmaceuticalPhase 3
47
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapyYuhanPre-clinical
33
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
PravastatinDaiichi SankyoPre-clinical
26
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
DS-5565 + Pregabalin + Placebo tablet + Placebo capsuleDaiichi SankyoPhase 3
40
tacrolimusAstellas PharmaPre-clinical
26
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
40
roxadustat + darbepoetin alfaAstellas PharmaPhase 2
35
Tamsulosin OCASAstellas PharmaApproved
43
ISV-305Sun PharmaceuticalPhase 3
40
ISV-305Sun PharmaceuticalPhase 3
40
Cefiderocol + Best Available TherapyShionogiPhase 3
40
Cefiderocol + Meropenem + LinezolidShionogiPhase 3
40
donepezil hclEisaiPhase 3
40
Zonegran + sugar pillEisaiPhase 3
40
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
40